Black Diamond Ownership

BDTX Stock  USD 2.20  0.01  0.45%   
Black Diamond holds a total of 56.59 Million outstanding shares. The majority of Black Diamond Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Black Diamond Therap to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Black Diamond. Please pay attention to any change in the institutional holdings of Black Diamond Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that nearly five hundred seventy-one thousand five hundred ten invesors are currently shorting Black Diamond expressing very little confidence in its future performance.
 
Shares in Circulation  
First Issued
2018-12-31
Previous Quarter
55.2 M
Current Value
56.5 M
Avarage Shares Outstanding
35.4 M
Quarterly Volatility
12.5 M
 
Covid
Some institutional investors establish a significant position in stocks such as Black Diamond in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Black Diamond, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Black Diamond Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Black Stock Ownership Analysis

About 99.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. Black Diamond Therap recorded a loss per share of 1.32. The entity had not issued any dividends in recent years. Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Black Diamond operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people. For more info on Black Diamond Therapeutics please contact the company at 617 252 0848 or go to https://www.blackdiamondtherapeutics.com.

Black Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Black Diamond is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Black Diamond Therapeutics backward and forwards among themselves. Black Diamond's institutional investor refers to the entity that pools money to purchase Black Diamond's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Citadel Advisors Llc2024-09-30
703.7 K
Point72 Asset Management, L.p.2024-09-30
697.1 K
Kennedy Capital Management Inc2024-09-30
657 K
Octagon Capital Advisors Lp2024-09-30
594 K
Driehaus Capital Management Llc2024-09-30
555.1 K
Boxer Capital Llc2024-09-30
506 K
T. Rowe Price Associates, Inc.2024-09-30
379.9 K
Northern Trust Corp2024-09-30
345.1 K
Connor Clark & Lunn Inv Mgmt Ltd2024-09-30
284.2 K
T. Rowe Price Investment Management,inc.2024-09-30
10.7 M
Bellevue Group Ag2024-09-30
8.5 M
Note, although Black Diamond's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Black Diamond Therap Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Black Diamond insiders, such as employees or executives, is commonly permitted as long as it does not rely on Black Diamond's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Black Diamond insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Black Diamond Outstanding Bonds

Black Diamond issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Black Diamond Therap uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Black bonds can be classified according to their maturity, which is the date when Black Diamond Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Black Diamond Corporate Filings

F4
16th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
8K
5th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F3
8th of August 2024
An amendment to the original Schedule 13D filing
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Black Stock Analysis

When running Black Diamond's price analysis, check to measure Black Diamond's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Black Diamond is operating at the current time. Most of Black Diamond's value examination focuses on studying past and present price action to predict the probability of Black Diamond's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Black Diamond's price. Additionally, you may evaluate how the addition of Black Diamond to your portfolios can decrease your overall portfolio volatility.